Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARγ agonist pioglitazone

[1]  A. McCullough.  The Epidemiology and Risk Factors of NASH , 2007 .

[2]  T. Noda,et al.  Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and -independent Pathways* , 2006, Journal of Biological Chemistry.

[3]  M. Czaja,et al.  Jnk1 but not jnk2 promotes the development of steatohepatitis in mice , 2006, Hepatology.

[4]  G. Marchesini,et al.  Insulin resistance: A metabolic pathway to chronic liver disease , 2005, Hepatology.

[5]  I. Leclercq,et al.  NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. , 2005, Gastroenterology.

[6]  L. Graves,et al.  Activation of Mitogen-Activated Protein Kinases by Peroxisome Proliferator-Activated Receptor Ligands: An Example of Nongenomic Signaling , 2005, Molecular Pharmacology.

[7]  E. Brunt,et al.  Pathology of nonalcoholic steatohepatitis. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  K. Ley,et al.  Macrophage differentiation to foam cells. , 2005, Current pharmaceutical design.

[9]  A. Bartke,et al.  Effects of caloric restriction on insulin pathway gene expression in the skeletal muscle and liver of normal and long-lived GHR-KO mice , 2005, Experimental Gerontology.

[10]  T. Kadowaki,et al.  Adiponectin and adiponectin receptors. , 2005, Endocrine reviews.

[11]  L. Guarente,et al.  Calorie restriction, SIRT1 and metabolism: understanding longevity , 2005, Nature Reviews Molecular Cell Biology.

[12]  M. Czaja,et al.  Hepatocyte CYP2E1 Overexpression and Steatohepatitis Lead to Impaired Hepatic Insulin Signaling* , 2005, Journal of Biological Chemistry.

[13]  P. Scherer,et al.  Adiponectin: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity? , 2005, International Journal of Obesity.

[14]  C. Sempoux,et al.  Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. , 2004, Journal of hepatology.

[15]  J. George,et al.  Fatty liver disease: NASH and related disorders , 2004 .

[16]  D. Befroy,et al.  Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.

[17]  I. Leclercq,et al.  Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice , 2004, Hepatology.

[18]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[19]  Weimin He,et al.  Muscle-specific Pparg deletion causes insulin resistance , 2003, Nature Medicine.

[20]  M. Reitman,et al.  Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.

[21]  B. Spiegelman,et al.  Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. , 2003, The Journal of clinical investigation.

[22]  M. Matsuda,et al.  Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. , 2003, Diabetes.

[23]  I. Leclercq,et al.  Central role of PPARα‐dependent hepatic lipid turnover in dietary steatohepatitis in mice , 2003, Hepatology.

[24]  Yu Wang,et al.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.

[25]  F. Gonzalez,et al.  Adipocyte-specific Gene Expression and Adipogenic Steatosis in the Mouse Liver Due to Peroxisome Proliferator-activated Receptor γ1 (PPARγ1) Overexpression* , 2003, The Journal of Biological Chemistry.

[26]  A. Koteish,et al.  Animal models of steatohepatitis. , 2002, Best practice & research. Clinical gastroenterology.

[27]  Margaret S. Wu,et al.  Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. , 2002, Diabetes.

[28]  D. Crabb,et al.  Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. , 2002, Gastroenterology.

[29]  Ansuman Bagchi,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Gene Expression Profile of Adipocyte Differentiation and Its Regulation by Peroxisome Proliferator-Activated , 2022 .

[30]  S. O’Rahilly,et al.  Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization. , 2002, Endocrinology.

[31]  Y. Terauchi,et al.  The Mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor γ (PPARγ) Deficiency and PPARγ Agonist Improve Insulin Resistance* , 2001, The Journal of Biological Chemistry.

[32]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[33]  G. Shulman,et al.  Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Staels,et al.  Peroxisome proliferator-activated receptors in inflammation control. , 2001, The Journal of endocrinology.

[35]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[36]  J. Auwerx,et al.  Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) Heterodimer , 2001, The Journal of experimental medicine.

[37]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[38]  T. Willson,et al.  Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor γ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues. , 2001, Endocrinology.

[39]  H. Tilg,et al.  Cytokines in alcoholic and nonalcoholic steatohepatitis. , 2000, The New England journal of medicine.

[40]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[41]  J. Auwerx,et al.  Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells , 2000, Diabetologia.

[42]  J. Olefsky.  Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .

[43]  I. Leclercq,et al.  CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. , 2000, The Journal of clinical investigation.

[44]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[45]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[46]  E. Kraegen,et al.  Development of Muscle Insulin Resistance After Liver Insulin Resistance in High-Fat–Fed Rats , 1991, Diabetes.

[47]  R. Green,et al.  The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. , 2004, Journal of hepatology.

[48]  J. Reddy,et al.  Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. , 2003, The Journal of biological chemistry.

[49]  D. Gerhold,et al.  Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. , 2002, Endocrinology.

[50]  S. O’Rahilly,et al.  Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. , 2002, Endocrinology.

[51]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[52]  Y. Terauchi,et al.  The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. , 2001, The Journal of biological chemistry.

[53]  K. Kaestner,et al.  Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). , 2001, Science.

[54]  J. Olefsky.  Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. , 2000, The Journal of clinical investigation.

[55]  Peter Olson,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and , 2022 .

[56]  G. Shulman,et al.  On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .